O-linked β-N-acetylglucosamine during hyperglycemia exerts both anti-inflammatory and pro-oxidative properties in the endothelial system by Rajapakse, Angana Gupta et al.
Elevated cellular levels of protein O-linked 
B-N-acetylglucosamine (O-GlcNAc) through hexosamine biosyn-
thesis pathway (HBP) are suggested to contribute to cardiovascular 
adverse effects under chronic hyperglycemic condition associated 
with oxidative stress and inflammation. Conversely, enhancing 
O-GlcNAc levels have also been demonstrated being protective 
against myocardial ischemia/reperfusion injury. We recently 
demonstrated that hyperglycemia increases oxidative stress and 
HBP flux in endothelial cells and enhances endothelial expres-
sion of vascular adhesion molecule-1 (VCAM-1) and intercellular 
adhesion molecule-1 (ICAM-1) in response to tumor necrosis 
factor-A (TNFA) through oxidative stress rather than HBP 
pathway. Here we present further complementary data showing 
that enhancing O-GlcNAc levels by glucosamine does not mimic 
hyperglycemia’s effect on TNFA-induced endothelial VCAM-1 
and ICAM-1 expression. Glucosamine however inhibits ICAM-1 
(not VCAM-1) expression and induces superoxide generation in 
the cells. The results further suggest that increased O-GlcNAc 
levels do not mediate the enhancing effect of hyperglycemia on 
the endothelial inflammatory responses to TNFA. In contrast, 
it exerts certain anti-inflammatory effects accompanied by pro-
oxidative properties. Further work should delineate the exact role 
of HPB pathway in different aspects of cardiovascular functions, 
especially those of diabetic cardiovascular complications.
Introduction
The posttranslational modification of serine and threonine 
residues of proteins by the O-linked attachment of the mono-
saccharide B-N-acetylglucosamine (O-GlcNAc), i.e., protein 
O-GlcNAcylation is emerging to play critical roles in regulation of 
wide spectrum of cellular functions including gene transcription, 
protein translation, proteasomal degradation and signal transduc-
tion.1 An elevated cellular level of O-GlcNAc is best described 
under chronic hyperglycemic condition in which an increased 
portion of glucose entering the cell is shunted from glycolysis 
to the hexosamine biosynthesis pathway (HBP).1 In the HBP 
pathway, glucose is converted to glucosamine-6-phosphate by 
the rate-limiting enzyme, L-glutamine:D-fructose-6-phosphate 
amidotransferase (GFAT). Glucosamine-6-phosphate is further 
metabolized to UDP-N-acetylglucosamine (UDP-GlcNAc) 
that serves as the major substrate for the formation of 
O-GlcNAc-modified proteins at serine and threonine residues 
catalysed by the UDP-GlcNAc:polypeptide O-B-N-acetyl-
glucosaminyltransferase (OGT).1 It has been suggested that 
elevated O-GlcNAc contributes to many deleterious effects of 
hyperglycemia, i.e., glucotoxicity including insulin resistance, 
diabetic cardiovascular damage associated with oxidative stress 
and inflammation.1-3
Conversely, there is a growing body of data demonstrating that 
enhancing O-GlcNAc level is protective against cellular injury, 
improves cell survival and reduces ischemia/reperfusion injury and 
myocardial infarction in animal models.4,5 The cellular O-GlcNAc 
levels are augmented under the acute non-diabetic stress condi-
tion i.e., ischemic preconditioning in the heart.6,7 An increase in 
O-GlcNAc level can be induced pharmacologically with the addi-
tion of exogenous glucosamine, which enters cells via the glucose 
transporter system and is phosphorylated to glucosamine-6-phos-
phate by hexokinase, thus bypassing GFAT and leading to a rapid 
increase in UDP-GlcNAc levels.8 Glucosamine has been shown to 
possess anti-inflammatory properties in variety of disease models 
including rheumatoid arthritis, cardiac allograft survival, balloon 
angioplasty induced arterial injury and cardiac ischemia/reperfu-
sion injury.9-11 The mechanisms of the apparent paradox of the 
cellular protective and deleterious effects of increased O-GlcNAc 
levels are not known. It is also not clear what is the functional role 
of the increased O-GlcNAc under the hyperglycemic condition in 
cardiovascular system.
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In our most recently published article,12 we showed that 
in cultured human umbilical vein endothelial cells (HUVEC) 
hyperglycemia increases oxidative stress and HBP flux, amplifies 
endothelial inflammatory responses i.e., VCAM-1 and ICAM-1 
expression in response to TNFA, and impairs endothelium-depen-
dent relaxations in isolated blood vessels mainly through oxidative 
stress rather than through HBP pathway. In the current article we 
present further complementary results showing functional roles of 
increased O-GlcNAc levels in regulation of endothelial inflamma-
tory responses and oxidative stress.
Results
Our recent study12 showed that hyperglycemia enhances 
endothelial expression of VCAM-1 and ICAM-1 in response to 
TNFA through increased oxidative stress rather than through 
increased cellular O-GlcNAc levels. In the current study, we further 
investigated whether treatment of the cells with glucosamine 
to enhance O-GlcNAc levels could mimic the hyperglycemia’s 
effect. In contrast to hyperglycemia,12 incubation of the cells with 
glucosamine (0.1 and 0.5 mmol/L) for 5 days did not enhance 
TNFA (1 ng/ml, 24 hours) induced VCAM-1 and ICAM-1 
protein levels, but inhibited ICAM-1 (not VCAM-1) expression 
(Fig. 1). The results further support our conclusion that increased 
O-GlcNAc does not contribute to the hyperglycemia-induced 
upregulation of endothelial expression of the adhesion molecules 
in response to TNFA. Of note, glucosamine itself had no signifi-
cant effects on the basal level of endothelial expression of the 
adhesion molecules (Fig. 1). In that recent study, we also showed 
that hyperglycemia further enhances oxidative stress in response 
to TNFA,12 this interaction between high glucose and TNFA
was however not observed between glucosamine and TNFA (Fig. 
2). Although incubation of the cells with glucosamine alone (0.5 
mol/L, 5 days) stimulated superoxide generation (similar to the 
high glucose condition12), it however did not significantly affect 
TNFA (1 ng/ml, 10 minutes)-induced superoxide anion produc-
tion as demonstrated by the dihydroethidium (DHE) fluorescence 
staining in the endothelial cells (Fig. 2), suggesting pro-oxidative 
properties of the HBP flux in endothelial cells.
Discussion
Protein O-GlcNAc modification has been recently shown to 
play important roles in regulation of variety of cellular functions.1
Under chronic hyperglycemic conditions of in vitro and in vivo 
model systems, increased HBP flux in different tissue/cells has 
been implicated in pathogenesis of insulin resistance and diabetic 
cardiovascular complications.13,14 For example, both high glucose 
and glucosamine increases O-GlcNAc modification of Akt/eNOS, 
leading to decreased activation of Akt/eNOS,15-17 an important 
vascular protective mechanism exerted by the vascular endothe-
lial cells.18 Moreover, it has been demonstrated that elevation of 
O-GlcNAc levels by high glucose, glucosamine and overexpression 
of GFAT enhances plasminogen activator inhibitor-1 (PAI-1) 
expression in mesangial cells via activation of Sp1 site.19 Increasing 
O-GlcNAc by glucosamine also reduces vascular sprouting in 
mouse aortic rings and in aortas from diabetic mouse models.20
All the studies implicate that increased HBP flux plays a role in the 
pathogenesis of diabetic cardiovascular complications.
The biological functions of HBP pathway in cardiovascular 
disease are recently challenged by a growing number of studies 
demonstrating that elevation of O-GlcNAc levels protects cardio-
myocytes from ischemia/reperfusion injury and reduces myocardial 
infarction in animal models.4-7,9 The cellular O-GlcNAc levels are 
transiently augmented under the acute non-diabetic stress condi-
tion i.e., ischemic preconditioning in the heart.6,7 Augmentation of 
O-GlcNAc with high glucose or glucosamine improves cell survival, 
whereas decrease in O-GlcNAc levels reduces cell viability.4-7,9
In our most recently published article,12 we investigated the 
roles of oxidative stress and HBP pathway in hyperglycemia-
induced endothelial inflammatory responses and endothelial 
dysfunction. We provided evidence that hyperglycemia increases 
oxidative stress and HBP flux in endothelial cells and enhances 
Figure 1. Effects of glucosamine on endothelial VCAM-1 and ICAM-1 
expression. (A) Immunoblotting demonstrates that treatment of HUVECs 
with glucosamine (0.1 or 0.5 mmol/L, 5 days) had no effects on VCAM-
1, but reduced ICAM-1 protein expression in response to TNFA (1 ng/
ml, 24 hours, n = 3). (B) Quantification of the above results. *p < 0.05 
vs. TNFA alone.
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O-GlcNAc level does not enhance TNFA-induced VCAM-1 and 
ICAM-1 protein expression. It however inhibits ICAM-1 (not 
VCAM-1) expression. Glucosamine itself does not have effects 
on endothelial expression of the adhesion molecules. The results 
thus provide further evidence that increased O-GlcNAc does not 
seem to play a role in hyperglycemia-induced upregulation of 
endothelial expression of the adhesion molecules in response to 
TNFA. The results are also in line with numerous experimental 
and clinical studies showing that glucosamine exhibits anti-
inflammatory effects and is used to treat several diseases associated 
with inflammation.9-11 The inhibition of ICAM-1 expression by 
glucosamine seems not mediated by blockade of oxidative stress, 
since glucosamine itself induces superoxide anion generation 
and does not inhibit TNFA-induced superoxide production as 
demonstrated by the DHE fluorescence staining in the endothelial 
cells. The pro-oxidative properties of glucosamine have also been 
reported in renal mesangial cells and pancreatic B-cells.21,22 The 
results implicate that elevation of O-GlcNAc may contribute to the 
oxidative stress associated with hyperglycemia.
In conclusion, the results presented here provide further 
evidence that HBP pathway does not mediate the enhancing effect 
of hyperglycemia on the endothelial inflammatory responses to 
TNFA. In contrast, glucosamine may exert certain anti-inflam-
matory effect in the context of endothelial adhesion molecule 
expression through enhancing O-GlcNAc level accompanied by 
pro-oxidative properties. The pro-oxidative and anti-inflammatory 
effects of glucosamine might explain the paradoxical effects of 
enhancing O-GlcNAc in cardiovascular system reported by afore-
mentioned various studies. Further work should delineate the 
definite role of HPB pathway in different aspects of cardiovascular 
functions, e.g., (a) cardiac vs. vascular injury; (b) effects of acute 
vs. chronic HBP flux; and (c) effects of diabetic vs. non-diabetic 
activation of HBP pathway.
Materials and Methods
Materials. D-(+)-glucosamine hydrochloride and chemicals for 
immunoblotting were purchased from Sigma (Buchs, Switzerland); 
antibodies against ICAM-1 and VCAM-1 were from Santa Cruz 
Biotechnology (Munningen, Switzerland); IRDye 800-conjugated 
affinity purified goat anti-rabbit IgG Fc was purchased from 
BioConcept (Allschwil, Switzerland); Alexa fluor 680-conjugated 
goat anti-mouse IgG (H + L) was from Invitrogen; dihy-
droethidium (DHE) was purchased from Invitrogen (Lucerne, 
Switzerland). Endothelial cell growth supplement pack was from 
PromoCell (Allschwil, Switzerland), and all cell culture media and 
materials were purchased from GIBCO (Lucerne, Switzerland).
Endothelial cell culture. Endothelial cells were isolated from 
human umbilical veins and characterized as described.12 Cells 
from the second to fourth passages were used. The endothelial cells 
were cultured in low-glucose (LG, 5.5 mmol/l) DMEM supple-
mented with 5% fetal calf serum (FCS), endothelial cell growth 
supplement and 0.6 nmol/l insulin. To study effects of O-GlcNAc 
on endothelial expression of adhesion molecules, the cells were 
incubated with 0.1 mmol/L or 0.5 mmol/l of glucosamine for 
4 days. The cells were then cultured in the medium containing 
endothelial inflammatory responses i.e., VCAM-1 and ICAM-1 
expression in response to TNFA through oxidative stress rather 
than through HBP pathway, since inhibition of superoxide 
generation by resveratrol prevents the endothelial expression of the 
adhesion molecules stimulated by high glucose plus TNFA without 
inhibition of the global O-GlcNAc levels in the cells exposed to 
hyperglycemia, although alterations of O-GlcNAc modification of 
some proteins can not be fully excluded. Importantly, azaserine, 
a widely used GFAT inhibitor not only inhibits HBP pathway 
under high glucose condition, but also exerts anti-oxidant and 
anti-inflammatory effects in the endothelial cells under normo-
glycemic condition in response to TNFA, when no increase in 
HBP flux occurs.12 The results implicate that azaserine exhibits 
anti-oxidative and anti-inflammatory effects in endothelial cells 
independently of inhibition of HBP pathway. These pharmaco-
logical effects of azaserine should be taken into account, when 
the substance is used to analyze the role of the HBP pathway in a 
biological system.
In the current article, we presented further results showing that 
incubation of the endothelial cells with glucosamine to augment 
Figure 2. Effects of glucosamine on endothelial superoxide anion gen-
eration. (A) Dihydroethidium (DHE) fluorescence staining shows that 
glucosamine itself (0.5 mmol/L, 5 days) induced superoxide generation 
in HUVECs and did not affect the effect of TNFA (1 ng/ml, 10 minutes, n 
= 3). (B) Quantification of the above results. *p < 0.05 and **p < 0.01 
vs. control.ht
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glucosamine supplemented with a lower concentration of FCS 
(1%) for 5 hours followed by the stimulation with TNFA (1 ng/
ml) for additional 24 hours.
ICAM-1 and VCAM-1 protein expression. Cell lysate prepara-
tion, 8% SDS-PAGE and protein transfer from SDS-PAGE gels 
to an Immobilon-P membrane (Millipore) were performed as 
described.12 The resultant membranes were first incubated with 
the individual primary antibody at room temperature for 2 to 
3 hours after blocking with 5% skimmed milk. The blots were 
then incubated with a corresponding anti-mouse (Alexa fluor 680 
conjugated) or anti-rabbit (IRDye 800 conjugated) secondary anti-
body (1:5,000) for 2 hours, and the quantification of the signals 
was performed using the Odyssey Application Software 1.2.
DHE staining for superoxide anion generation. Superoxide 
anion generation was analyzed as described.12 Images were 
obtained with Zeiss fluorescence microscopy. The intensity of the 
fluorescence was quantified by Image J software.
Statistical analysis. All data were given as means ± SE. The 
ANOVA with Bonferroni post hoc test was used for statistical 
analysis. A two-tailed value of p < 0.05 was considered to indicate 
a statistically significant difference.
Acknowledgements
We would like to thank Jean Ruffieux for technical assistance 
in isolation of endothelial cells. This study was supported by Swiss 
National Science Foundation (Nr. 3100A0-105917 and 310000-
120435/1), Swiss Heart Foundation, and the Swiss Cardiovascular 
Research and Training Network (SCRTN) Programme. J.M.C. 
was partially supported by Roche Research Foundation.
References
1. Laczy B, Hill BG, Wang K, Paterson AJ, White CR, Xing D, et al. Protein 
O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol 
Heart Circ Physiol 2009; 296:13-28.
2. Yang X, Ongusaha PP, Miles PD, Havstad JC, Zhang F, So WV, et al. Phosphoinositide 
signalling links O-GlcNAc transferase to insulin resistance. Nature 2008; 451:964-9.
3. Copeland RJ, Bullen JW, Hart GW. Cross-talk between GlcNAcylation and phospho-
rylation: roles in insulin resistance and glucose toxicity. Am J Physiol Endocrinol Metab 
2008; 295:17-28.
4. Ngoh GA, Facundo HT, Hamid T, Dillmann W, Zachara NE, Jones SP. Unique hexo-
saminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/
reoxygenation injury. Circ Res 2009; 104:41-9.
5. Champattanachai V, Marchase RB, Chatham JC. Glucosamine protects neonatal car-
diomyocytes from ischemia-reperfusion injury via increased protein O-GlcNAc and 
increased mitochondrial Bcl-2. Am J Physiol Cell Physiol 2008; 294:1509-20.
6. Jones SP, Zachara NE, Ngoh GA, Hill BG, Teshima Y, Bhatnagar A, et al. Cardioprotection 
by N-acetylglucosamine linkage to cellular proteins. Circulation 2008; 117:1172-82.
7. Fulop N, Zhang Z, Marchase RB, Chatham JC. Glucosamine cardioprotection in per-
fused rat hearts associated with increased O-linked N-acetylglucosamine protein modifi-
cation and altered p38 activation. Am J Physiol Heart Circ Physiol 2007; 292:2227-36.
8. Marshall S, Nadeau O, Yamasaki K. Dynamic actions of glucose and glucosamine on 
hexosamine biosynthesis in isolated adipocytes: differential effects on glucosamine 6-phos-
phate, UDP-N-acetylglucosamine and ATP levels. J Biol Chem 2004; 279:35313-9.
9. Zou L, Yang S, Champattanachai V, Hu S, Chaudry IH, Marchase RB, Chatham JC. 
Glucosamine improves cardiac function following trauma-hemorrhage by increased 
protein O-GlcNAcylation and attenuation of NF{kappa}B signaling. Am J Physiol Heart 
Circ Physiol 2009; 296:515-23.
10. Ma L, Rudert WA, Harnaha J, Wright M, Machen J, Lakomy R, et al. Immunosuppressive 
effects of glucosamine. J Biol Chem 2002; 277:39343-9.
11. Xing D, Feng W, Not LG, Miller AP, Zhang Y, Chen YF, et al. Increased protein 
O-GlcNAc modification inhibits inflammatory and neointimal responses to acute 
endoluminal arterial injury. Am J Physiol Heart Circ Physiol 2008; 295:335-42.
12. Rajapakse AG, Ming XF, Carvas JM, Yang Z. The hexosamine biosynthesis inhibitor 
azaserine prevents endothelial inflammation and dysfunction under hyperglycemic con-
dition through antioxidant effects. Am J Physiol Heart Circ Physiol 2009; 296:815-22.
ht
tp
://
do
c.
re
ro
.c
h
4
